Dr. Christopher Cannon, a renowned cardiologist and professor at Harvard, dives into the fascinating world of Pragmatic Clinical Trials alongside Dr. Thomas Nero. They discuss the EVOLVE-MI trial, highlighting the early use of Evolocumab post-myocardial infarction. The conversation unveils the importance of real-world data, patient-centric trial design, and customizing LDL cholesterol targets to enhance cardiovascular care. Cannon emphasizes the need for streamlined participation to improve patient outcomes and the future potential of evolving research strategies.